The more advanced stage of the underlying cardiac disease is also reflected in the proportion of severely symptomatic patients (88.4% NYHA class III/IV; COAPT: 57%; Mitra-FR: 63.1%) and the more pronounced elevation of NT-proBNP values (median 4567 ng/l (IQR 1957; 10,630 ng/l), mean 9392 ng/l ± 12,465 ng/l; COAPT: mean 5174 ng/l ± 6566 ng/l; Mitra-FR: median 3407 ng/l (IQR 1948–6790 ng/l)). The gene discussed is NPPB; the disease is heart disorder.